Dag Josefsen
Papers
1
Total Citations
30
H-Index
1
About
Dag Josefsen is a pioneering translational researcher in cancer immunotherapy, with a primary focus on dendritic cell (DC) vaccines for high-risk prostate cancer. His landmark work includes leading a long-term, first-in-man Phase I/II study investigating an adjuvant personalized DC vaccine administered after robot-assisted radical prostatectomy. This study, which has garnered 30 citations, demonstrated the feasibility and safety of targeting biochemical relapse (BCR)—a critical window where patients face a high risk of developing non-curative disease. Josefsen’s major contribution lies in bridging preclinical immunology to clinical application, showing that patient-specific DC vaccines can be effectively integrated into standard surgical care. By focusing on the adjuvant setting, his research addresses a significant unmet need: reducing recurrence rates in men with aggressive prostate cancer. His work has helped lay the groundwork for larger trials exploring immune-based strategies to prevent metastatic progression. Through rigorous clinical investigation, Josefsen continues to advance the promise of personalized cellular immunotherapy, offering new hope for patients with high-risk disease.
Research Focus
Key Achievements
Top Papers
- 1